{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-063955","form_type":"8-K","ticker":"ACLX","cik":"0001786205","company_name":"Arcellx, Inc.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.172399+00:00","generated_at":"2026-05-16T01:13:14.569009+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B","bullets":["Per-share consideration: $115 cash at closing + one CVR worth up to $5 contingent on anito-cel cumulative sales exceeding $6B by Dec 31, 2029.","Gilead gains full control of anito-cel, a BCMA-directed CAR T-cell therapy currently under FDA review with a PDUFA date of Dec 23, 2026.","Support stockholders (entities affiliated with NEA, SR One, directors, officers) holding ~10.3% of shares have agreed to tender in the offer.","Transaction is structured as a tender offer followed by a Section 251(h) merger; Arcellx may pay a $260M termination fee under specified circumstances.","Arcellx will conduct business in ordinary course and is subject to a no-shop restriction prior to the Offer Acceptance Time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-063955","json":"https://secwatch.observer/filing/0001193125-26-063955.json","markdown":"https://secwatch.observer/filing/0001193125-26-063955.md","text":"https://secwatch.observer/filing/0001193125-26-063955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/0001193125-26-063955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/d112937d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:13:14.569009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a28aec0de684418135df2d0e5cf77a43c699493","claim":"Arcellx, Inc. entered into Agreement and Plan of Merger with Gilead Sciences, Inc. (effective 2026-02-22).","evidence_excerpt":"On February 22, 2026, Arcellx, Inc., a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Gilead Sciences, Inc., a Delaware corporation (“ Parent ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1786205/000119312526063955/0001193125-26-063955-index.htm","confidence":0.99,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Gilead Sciences, Inc."},{"label":"Effective","value":"2026-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}